CRP-Based Cardiovascular Risk Assessment: New Conventional CRP Assay Fit for Purpose?

Area of Science:

• Clinical Chemistry
• Cardiovascular Medicine
• Biomarker Analysis

Background:

• Subclinical inflammation is implicated in cardiovascular disease development.
• Current guidelines recommend high-sensitivity C-reactive protein (hs-CRP) assays for cardiovascular risk assessment.
• Newer conventional CRP assays offer lower detection limits, potentially improving accessibility.

Purpose of the Study:

• To evaluate the performance of a new conventional C-reactive protein (CRP) assay compared to high-sensitivity CRP (hs-CRP) for cardiovascular risk assessment.
• To determine if regular CRP assays meet the precision requirements for cardiovascular risk stratification.

Main Methods:

• A multisite comparative study was conducted.
• The Tina-quant conventional CRP assay was compared against established hs-CRP assays.
• Assay precision was evaluated at critical cutpoints (1.00, 2.00, and 3.00 mg/L).

Main Results:

• A satisfactory concordance was observed between the regular CRP assay and the hs-CRP assay.
• Both assays demonstrated analytical precision meeting requirements at tested cutpoints.
• The new conventional CRP assay can measure CRP levels down to 0.6 mg/L.

Conclusions:

• The new conventional CRP assay is suitable for cardiovascular risk assessment.
• Utilizing regular CRP assays offers potential operational and financial advantages over hs-CRP assays.
• This may broaden the accessibility of CRP testing for cardiovascular risk evaluation.